Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Promega launches XpressAmp Direct Amplification Reagents

May 2021—Promega Corp. released its XpressAmp Direct Amplification Reagents. The product contains components for performing extraction-free preparation of viral samples for PCR-based amplification using commonly available PCR reagents from samples collected by nasopharyngeal swab in universal or viral transport medium. The reagents allow the user to perform direct amplification analysis in RT-qPCR following a 10-minute, room-temperature incubation.

FDA authorizes two Quidel SARS-CoV-2 tests

May 2021—Quidel received FDA emergency use authorization allowing the company to market its QuickVue At-Home OTC COVID-19 Test for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days, with at least 24 hours, but no more than 36 hours, between tests. This test is authorized for nonprescription home use with self-collected direct anterior nares specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals who are two years old or older.

Adaptive launches T-Detect COVID test

May 2021—Adaptive Biotechnologies Corp. launched its T-Detect COVID, a clinical T-cell–based test to identify people who have evidence of a cellular immune response against SARS-CoV-2. It uses Adaptive’s immunoSEQ technology to sequence T-cell receptors from a blood sample and identifies TCRs that the company has mapped for recognition of SARS-CoV-2 antigens.

Qiagen launches QIAcube Connect MDx

May 2021—Qiagen announced the global launch of the CE-IVD-marked QIAcube Connect MDx, a flexible platform for automated sample processing available now to molecular diagnostic laboratories in the U.S., Canada, the European Union, and other markets worldwide.

BD SARS-CoV-2, flu A+B test gets EUA, CE mark

April 2021—BD announced FDA emergency use authorization for its BD SARS-CoV-2/Flu assay, a molecular diagnostic test for SARS-CoV-2 and influenza A and B that provides results in two to three hours. The test also has been CE marked to the IVD directive.

Bio SB launches antibodies for SARS-CoV-2

April 2021—Bio SB has developed a new panel of SARS-CoV-2 antibodies to identify the COVID-19 virus, its receptors, and its cytokines by immunohistochemistry and immunofluorescence on formalin-fixed, paraffin-embedded biopsies. The antibodies identify ACE2, CD147, and TMPRSS2 receptors and include markers for immune response factors and vascular cells, with the intention to assess the pathological damage caused by COVID-19, cytokine storm syndrome, and coagulopathy, using single and multiplex IHC and immunofluorescence on FFPE tissues.

Bio-Rad enhances InteliQ QC line

April 2021—Bio-Rad Laboratories has enhanced its InteliQ liquid quality controls product line. InteliQ products have improved open-vial stability, and they are now available on Abbott Alinity and Roche Cobas systems.

QIAsphere cloud-based connectivity solution

April 2021—Qiagen launched its QIAsphere cloud-based platform, which will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.

MARKETPLACE

TRENDING